These are top 10 stocks traded on the Robinhood UK platform in July
On Wednesday, Sana Biotechnology (NASDAQ:SANA), currently trading at $1.71, maintained its Buy rating and $11.00 price target from H.C. Wainwright. The firm’s analyst, Emily Bodnar, provided insights into the company’s recent presentation at the New York Stem Cell Foundation (NYSCF) Conference. According to InvestingPro data, analyst targets for SANA range from $5 to $15, with the stock showing significant volatility in recent months. Sana showcased updated 12-week data for its innovative therapy, UP421, aimed at treating patients with Type 1 diabetes (T1D).
The treatment, a hypoimmune-modified pancreatic islet cell therapy, is notable for its administration without the need for immunosuppression. The ongoing trial, which is first-in-human and investigator sponsored, is conducted in collaboration with Uppsala University Hospital. The recent data follows a previous report from January that presented promising 4-week safety and efficacy results. InvestingPro analysis reveals the company maintains a strong liquidity position with a current ratio of 3.54, though it’s currently burning through cash rapidly.
The latest findings revealed that the patient, who initially had undetectable C-peptide levels, showed a sustained presence of this biomarker for insulin production at 12 weeks post-transplantation. The levels slightly decreased from week 8 but remained within the expected range. After a mixed meal tolerance test, the patient’s C-peptide levels rose, indicating continued insulin secretion in response to food intake.
The study also confirmed a favorable safety profile for UP421, with no signs of inflammation or graft rejection, suggesting that the HIP-modified islets can avoid detection by both innate and adaptive immune systems. Sana Biotechnology reiterated its intention to release additional follow-up data from the ongoing study throughout the year, which will be made available through peer-reviewed publications and presentations at scientific conferences. With the next earnings report due on May 13, investors can access comprehensive analysis and 12 additional exclusive insights through InvestingPro’s detailed research reports.
In other recent news, Sana Biotechnology reported its fourth-quarter and full-year 2024 earnings, revealing a narrower-than-expected loss with an adjusted loss of $0.23 per share, beating analyst estimates of $0.24. The company also highlighted positive preliminary 12-week clinical data from its ongoing type 1 diabetes study, which showed promising results for its hypoimmune-modified pancreatic islet cells. These cells demonstrated stable C-peptide production, suggesting effective insulin secretion without immunosuppression, a significant advancement in diabetes treatment. Sana’s financial position remains strong, with a cash reserve of $152.5 million, which is expected to support operations into 2026.
Sana Biotechnology’s stock received an upgrade from Citizens JMP, changing the rating from Market Perform to Market Outperform, with a new price target set at $5.00. This upgrade was influenced by the company’s positive trial outcomes and financial stability. H.C. Wainwright maintained a Buy rating on Sana’s shares with an $11.00 price target, emphasizing the potential of Sana’s hypoimmune technology platform. The company’s ongoing trials and expected data releases in 2025 for its SC291 and SC262 therapies further bolster confidence among analysts. Sana also plans to file investigational new drug applications for additional therapies as early as 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.